Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T with different PA2024 antigen concentrations in mCRPC
NCT00715078Phase 2Completed
- Sponsor
- Dendreon
- Start
- Oct 2008
- Primary completion
- Apr 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Dendreon. Primary endpoint: Cumulative CD54 Upregulation Ratio at Month 6. Started Oct 2008; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00715078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715078.